Grifols (GRFS) Net Debt Issuances and Repayments (2017 - 2020)
Grifols (GRFS) posted Net Debt Issuances and Repayments of -$130.2 million for Q1 2020, up 59.92% quarter-over-quarter from -$324.9 million in Q4 2019, and up 75.96% year-on-year from -$74.0 million in Q2 2019.
Grifols (GRFS) Net Debt Issuances and Repayments (2017 - 2020) Analysis & Trends
Grifols (GRFS) has reported Net Debt Issuances and Repayments for 4 consecutive years, with -$130.2 million the latest figure, recorded in Q1 2020.
- Net Debt Issuances and Repayments for Q1 2020 came in at -$130.2 million, up 75.96% year-over-year; the trailing twelve-month figure through Mar 2020 was -$615.9 million (down 368.98% YoY), and the FY2019 annual result was -$324.9 million, down 185.27% from the prior year.
- Net Debt Issuances and Repayments was -$130.2 million for Q1 2020 at Grifols, up from -$324.9 million in the prior quarter.
- Over five years, Net Debt Issuances and Repayments peaked at $381.1 million in Q4 2018 and troughed at -$541.8 million in Q1 2019.
- Average Net Debt Issuances and Repayments over 4 years is -$61.4 million, with a median of $8.0 million recorded in 2017.
- Year-over-year, Net Debt Issuances and Repayments surged 4662.07% in 2018 and slumped 2629.63% in 2019.
- Over 4 years, Net Debt Issuances and Repayments stood at $8.0 million in 2017, then soared by 4662.07% to $381.1 million in 2018, then tumbled by 185.27% to -$324.9 million in 2019, then jumped by 59.92% to -$130.2 million in 2020.
- Per Business Quant data, the three most recent Net Debt Issuances and Repayments figures were -$130.2 million in Q1 2020, -$324.9 million in Q4 2019, and -$541.8 million in Q1 2019.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Debt Issuance (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | - |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | - |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | - |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | 1.57 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | - |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | - |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | - |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | - |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Grifols | - | - | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2020 | -130.24 Mn |
| Mar 31, 2020 | -130.24 Mn |
| Dec 31, 2019 | -324.92 Mn |
| Dec 31, 2019 | -324.92 Mn |
| Mar 31, 2019 | -541.80 Mn |
| Mar 31, 2019 | -541.80 Mn |
| Dec 31, 2018 | 381.05 Mn |
| Dec 31, 2018 | 381.05 Mn |
| Mar 31, 2018 | 21.42 Mn |
| Mar 31, 2018 | 21.42 Mn |
| Dec 31, 2017 | 8.00 Mn |
| Dec 31, 2017 | 8.00 Mn |
| Mar 31, 2017 | 156.72 Mn |
| Mar 31, 2017 | 156.72 Mn |